Selective Estrogen Receptor Down-Regulator and Selective Estrogen Receptor Modulators Differentially Regulate Lactotroph Proliferation

Background We recently reported that estrogen receptor α (ERα), even in absence of estrogen (E2), plays a critical role in lactotroph homeostasis. The anti-estrogen ICI 182780 (ICI), but not tamoxifen or raloxifene, rapidly promoted the degradation of ERα, and inhibited cell proliferation. However, all three ER antagonists suppressed PRL release, suggesting that receptor occupation is sufficient to inhibit prl gene expression whereas receptor degradation is required to suppress lactotroph proliferation. In this study our objective was to determine whether ERα degradation versus occupation, differentially modulates the biological outcome of anti-estrogens. Principal Findings Using the rat lactotroph cell line, GH3 cells, we report that ICI induced proteosome mediated degradation of ERα. In contrast, an ERα specific antagonist, MPP, that does not promote degradation of ERα, did not inhibit cell proliferation. Further, ICI, but not MPP, abolished anchorage independent growth of GH3 cells. Yet, both ICI and MPP were equally effective in suppressing prl expression and release, as well as ERE-mediated transcriptional activity. Conclusion Taken together, our results demonstrate that in lactotrophs, ERα degradation results in decreased cell proliferation, whereas ERα occupation by an antagonist that does not promote degradation of ERα is sufficient to inhibit prl expression.

[1]  F. Collins,et al.  Mouse Embryo Fibroblasts Lacking the Tumor Suppressor Menin Show Altered Expression of Extracellular Matrix Protein Genes , 2007, Molecular Cancer Research.

[2]  S. Kansra,et al.  Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release , 2005, Molecular and Cellular Endocrinology.

[3]  D. Sarkar,et al.  Distinct signaling pathways mediate stimulation of cell cycle progression and prevention of apoptotic cell death by estrogen in rat pituitary tumor PR1 cells. , 2003, Molecular biology of the cell.

[4]  G. Leclercq,et al.  Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  B. Katzenellenbogen,et al.  Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression , 2003, Molecular and Cellular Endocrinology.

[6]  S. Belcher,et al.  Estrogens and ICI182,780 (Faslodex) Modulate Mitosis and Cell Death in Immature Cerebellar Neurons via Rapid Activation of p44/p42 Mitogen-Activated Protein Kinase , 2003, The Journal of Neuroscience.

[7]  B. Staels,et al.  Peroxisome Proliferator-activated Receptor α (PPARα) Turnover by the Ubiquitin-Proteasome System Controls the Ligand-induced Expression Level of Its Target Genes* , 2002, The Journal of Biological Chemistry.

[8]  S. Melmed,et al.  Proteasome inhibitors induce apoptosis in growth hormone- and prolactin-secreting rat pituitary tumor cells. , 2002, The Journal of endocrinology.

[9]  B. Katzenellenbogen,et al.  Antagonists Selective for Estrogen Receptor α. , 2002, Endocrinology.

[10]  Li Zhao,et al.  Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  E. Alarid,et al.  Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. , 1999, Molecular endocrinology.

[12]  O. Jänne,et al.  Ubc9 Interacts with the Androgen Receptor and Activates Receptor-dependent Transcription* , 1999, The Journal of Biological Chemistry.

[13]  M. Tsai,et al.  The Angelman Syndrome-Associated Protein, E6-AP, Is a Coactivator for the Nuclear Hormone Receptor Superfamily , 1999, Molecular and Cellular Biology.

[14]  J. Polman,et al.  ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .

[15]  M. Imhof,et al.  Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors , 1996, Molecular and cellular biology.

[16]  C. Newton Estrogen receptor blockade by the pure antiestrogen, ZM 182780, induces death of pituitary tumour cells , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[17]  R. Thampan,et al.  Ubiquitination of the rat uterine estrogen receptor: dependence on estradiol. , 1995, Biochemical and biophysical research communications.

[18]  D. Moore,et al.  Interaction of thyroid-hormone receptor with a conserved transcriptional mediator , 1995, Nature.

[19]  A. Gutierrez-Hartmann,et al.  Activation of the prolactin promoter in transfected GH3 cells by posterior pituitary cells. , 1994, Endocrinology.

[20]  M. Parker,et al.  The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. , 1993, Journal of cell science.

[21]  M. Parker,et al.  Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Wakeling,et al.  A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.

[23]  S. Fawell,et al.  Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[24]  E. Jensen,et al.  Estrogen-binding substances of target tissues. , 1969, Science.

[25]  E. Jensen,et al.  Estrogen-binding substances of target tissues. , 1967, Steroids.

[26]  B. Katzenellenbogen,et al.  Antagonists selective for estrogen receptor alpha. , 2002, Endocrinology.

[27]  B. Staels,et al.  Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. , 2002, The Journal of biological chemistry.

[28]  B. O’Malley,et al.  FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent. , 2001, Nature cell biology.

[29]  B. O’Malley,et al.  FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent , 2000, Nature Cell Biology.

[30]  J. Gustafsson,et al.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. , 1997, Science.

[31]  J. Polman,et al.  ER beta: identification and characterization of a novel human estrogen receptor. , 1996, FEBS letters.